H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ABEO stock, giving a Buy rating on March 20.
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding Abeona Therapeutics. The imminent potential approval of their lead candidate, prademagene zamikeracel (pz-cel), by the FDA is a significant driver. The product is expected to be a leading treatment for recessive dystrophic epidermolysis bullosa (RDEB) patients, either as a standalone therapy or in combination with existing treatments. Kapoor believes that the efficacy and durability of pz-cel, along with its competitive edge over existing treatments like Filsuvez, position it well in the market.
Additionally, Abeona’s strategic preparations for commercialization, including engaging with treatment centers and payers, further support the positive outlook. The company’s recent patent acquisitions extend protection for pz-cel, enhancing its market potential. Financially, Abeona’s narrowing net losses and projected revenue growth indicate a path to profitability by late 2026, driven by pz-cel sales. These elements collectively underpin Kapoor’s confidence in the stock’s potential, justifying the Buy rating.
According to TipRanks, Kapoor is an analyst with an average return of -21.4% and a 29.24% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Sarepta Therapeutics, and Summit Therapeutics.
In another report released on March 20, Oppenheimer also reiterated a Buy rating on the stock with a $16.00 price target.